Literature DB >> 12828094

Neostigmine and polyethylene glycol electrolyte solution for the therapy of acute hepatic encephalopathy with liver cirrhosis and ascites.

Takayoshi Kiba1, Kazushi Numata, Satoru Saito.   

Abstract

We treated a 75-year-old man who had non-B and non-C, and Child's class C liver cirrhosis and acute hepatic encephalopathy with neostigmine and polyethylene glycol electrolyte solution. He received repeated transcatheter artrial embolization and percutaneous ethanol injection combination therapy for multiple hepatocellular carcinomas, which controlled his disease for 25 months from the first treatment. He was admitted in a state of hepatic coma after being found unresponsive at his home. With the consent of the patient's family, we gave him 1.0 mg of neostigmine intramuscularly to improve his peristaltic movement, and 2 L of polyethylene glycol electrolyte solution through a nasogastric tube for 4 hours to reduce the production and absorption of gut-derived toxins of nitrogenous compounds. Using these treatments, the blood ammonia level decreased to the normal range within 8 hours, and the coma disappeared after 2 days. We suggest that a combination approach of neostigmime and polyethylene glycol electrolyte solution may be one of the most effective treatments for acute hepatic encephalopathy associated with liver cirrhosis and ascites.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12828094

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

1.  Neostigmine for the treatment of acute hepatic encephalopathy with acute intestinal pseudo-obstruction in a cirrhotic patient.

Authors:  Chang Hwan Park; Young Eun Joo; Hyun Soo Kim; Sung Kyu Choi; Jong Sun Rew; Sei Jong Kim
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

2.  Effect of neostigmine on organ injury in murine endotoxemia: missing facts about the cholinergic antiinflammatory pathway.

Authors:  Seda B Akinci; Nadir Ulu; Omer Z Yondem; Pinar Firat; M Oguz Guc; Meral Kanbak; Ulku Aypar
Journal:  World J Surg       Date:  2005-11       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.